Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.71
JNJ's Cash to Debt is ranked lower than
56% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.75 vs. JNJ: 1.71 )
Ranked among companies with meaningful Cash to Debt only.
JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 1.63 Max: 6.28
Current: 1.71
0.46
6.28
Equity to Asset 0.53
JNJ's Equity to Asset is ranked lower than
64% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. JNJ: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.67
Current: 0.53
0.5
0.67
Interest Coverage 41.02
JNJ's Interest Coverage is ranked higher than
57% of the 464 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. JNJ: 41.02 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.54 Max: 208.73
Current: 41.02
28.29
208.73
F-Score: 6
Z-Score: 5.42
M-Score: -2.64
WACC vs ROIC
7.38%
26.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 25.89
JNJ's Operating margin (%) is ranked higher than
88% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. JNJ: 25.89 )
Ranked among companies with meaningful Operating margin (%) only.
JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 25.14 Max: 28.2
Current: 25.89
22.36
28.2
Net-margin (%) 21.92
JNJ's Net-margin (%) is ranked higher than
89% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. JNJ: 21.92 )
Ranked among companies with meaningful Net-margin (%) only.
JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 21.99
Current: 21.92
14.87
21.99
ROE (%) 21.70
JNJ's ROE (%) is ranked higher than
85% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. JNJ: 21.70 )
Ranked among companies with meaningful ROE (%) only.
JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 30.17
Current: 21.7
17.02
30.17
ROA (%) 11.59
JNJ's ROA (%) is ranked higher than
83% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.69 vs. JNJ: 11.59 )
Ranked among companies with meaningful ROA (%) only.
JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 17.08
Current: 11.59
8.93
17.08
ROC (Joel Greenblatt) (%) 88.45
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.05 vs. JNJ: 88.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 114.87
Current: 88.45
65.66
114.87
Revenue Growth (3Y)(%) 1.40
JNJ's Revenue Growth (3Y)(%) is ranked lower than
63% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. JNJ: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.20 Max: 13.8
Current: 1.4
1.4
13.8
EBITDA Growth (3Y)(%) 9.30
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. JNJ: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 11.20 Max: 17.3
Current: 9.3
-6.6
17.3
EPS Growth (3Y)(%) 12.40
JNJ's EPS Growth (3Y)(%) is ranked higher than
59% of the 505 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. JNJ: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 12.20 Max: 18.2
Current: 12.4
-8.6
18.2
» JNJ's 10-Y Financials

Financials (Next Earnings Date: 2016-07-19)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

JNJ Guru Trades in Q2 2015

David Dreman 6,648 sh (New)
Sarah Ketterer 1,207,926 sh (+41.27%)
John Rogers 782,026 sh (+19.02%)
Manning & Napier Advisors, Inc 3,292,140 sh (+17.49%)
Paul Tudor Jones 63,433 sh (+13.16%)
John Buckingham 63,439 sh (+2.51%)
Ruane Cunniff 77,357 sh (+1.87%)
Mairs and Power 2,158,264 sh (+1.86%)
Ken Fisher 10,641,756 sh (+1.77%)
Jeff Auxier 91,926 sh (+0.27%)
Richard Pzena 1,174,169 sh (+0.01%)
Michael Price 25,000 sh (unchged)
John Hussman 1,325 sh (unchged)
RS Investment Management 8,578 sh (unchged)
T Rowe Price Equity Income Fund 4,633,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Snow 3,270 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,632,757 sh (-0.28%)
First Eagle Investment 1,610,098 sh (-1.09%)
Murray Stahl 29,841 sh (-2.72%)
Jeremy Grantham 12,907,199 sh (-2.73%)
Tweedy Browne 3,918,801 sh (-3.38%)
PRIMECAP Management 11,370,350 sh (-4.12%)
Dodge & Cox 38,235 sh (-4.38%)
Mario Gabelli 315,150 sh (-5.40%)
Richard Perry 292,729 sh (-6.36%)
Yacktman Fund 3,500,000 sh (-10.26%)
Donald Yacktman 7,441,948 sh (-11.75%)
Yacktman Focused Fund 2,500,000 sh (-16.67%)
Pioneer Investments 2,068,266 sh (-21.14%)
Ray Dalio 194,993 sh (-27.27%)
» More
Q3 2015

JNJ Guru Trades in Q3 2015

John Burbank 32,624 sh (New)
Jim Simons 392,000 sh (New)
Charles Brandes 118,509 sh (New)
Chuck Royce 9,000 sh (New)
Louis Moore Bacon 63,428 sh (New)
Manning & Napier Advisors, Inc 4,406,762 sh (+33.86%)
Sarah Ketterer 1,593,359 sh (+31.91%)
RS Investment Management 10,457 sh (+21.90%)
Jeff Auxier 110,226 sh (+19.91%)
Pioneer Investments 2,381,190 sh (+15.13%)
John Rogers 884,154 sh (+13.06%)
Yacktman Focused Fund 2,600,000 sh (+4.00%)
Yacktman Fund 3,600,000 sh (+2.86%)
John Buckingham 64,896 sh (+2.30%)
Donald Yacktman 7,560,334 sh (+1.59%)
Tom Gayner 582,200 sh (+1.39%)
Murray Stahl 30,179 sh (+1.13%)
Mairs and Power 2,181,707 sh (+1.09%)
Mario Gabelli 317,847 sh (+0.86%)
T Rowe Price Equity Income Fund 4,672,800 sh (+0.86%)
Ken Fisher 10,689,483 sh (+0.45%)
Robert Olstein 71,000 sh (unchged)
John Hussman 1,325 sh (unchged)
David Carlson 460,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Richard Snow 3,270 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Perry 292,729 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Pzena 1,174,169 sh (unchged)
David Dreman Sold Out
Ruane Cunniff 76,400 sh (-1.24%)
Barrow, Hanley, Mewhinney & Strauss 15,399,839 sh (-1.49%)
First Eagle Investment 1,585,928 sh (-1.50%)
Tweedy Browne 3,855,936 sh (-1.60%)
Dodge & Cox 36,935 sh (-3.40%)
PRIMECAP Management 10,575,867 sh (-6.99%)
Jeremy Grantham 11,529,743 sh (-10.67%)
Ray Dalio 167,593 sh (-14.05%)
Paul Tudor Jones 47,878 sh (-24.52%)
» More
Q4 2015

JNJ Guru Trades in Q4 2015

Joel Greenblatt 39,586 sh (New)
John Hussman 26,325 sh (+1886.79%)
John Burbank 68,755 sh (+110.75%)
First Eagle Investment 3,032,177 sh (+91.19%)
Jim Simons 655,300 sh (+67.17%)
Pioneer Investments 3,824,174 sh (+60.60%)
Charles Brandes 151,094 sh (+27.50%)
Mario Gabelli 332,287 sh (+4.54%)
Tom Gayner 605,200 sh (+3.95%)
John Buckingham 65,746 sh (+1.31%)
Ken Fisher 10,815,964 sh (+1.18%)
Mairs and Power 2,184,308 sh (+0.12%)
Richard Pzena 1,174,524 sh (+0.03%)
Chuck Royce 9,000 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
T Rowe Price Equity Income Fund 4,672,800 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Carlson 460,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Louis Moore Bacon Sold Out
PRIMECAP Management 10,543,562 sh (-0.31%)
Richard Snow 3,260 sh (-0.31%)
Barrow, Hanley, Mewhinney & Strauss 15,342,046 sh (-0.38%)
Murray Stahl 29,941 sh (-0.79%)
Paul Tudor Jones 46,483 sh (-2.91%)
Donald Yacktman 7,316,129 sh (-3.23%)
Yacktman Focused Fund 2,500,000 sh (-3.85%)
Dodge & Cox 35,435 sh (-4.06%)
Tweedy Browne 3,693,349 sh (-4.22%)
Jeff Auxier 105,426 sh (-4.35%)
John Rogers 831,664 sh (-5.94%)
Sarah Ketterer 1,497,289 sh (-6.03%)
RS Investment Management 9,592 sh (-8.27%)
Jeremy Grantham 9,970,431 sh (-13.52%)
Manning & Napier Advisors, Inc 3,769,800 sh (-14.45%)
Ruane Cunniff 64,753 sh (-15.24%)
Ray Dalio 109,693 sh (-34.55%)
» More
Q1 2016

JNJ Guru Trades in Q1 2016

Jim Chanos 29,730 sh (New)
Diamond Hill Capital 1,969 sh (New)
David Rolfe 5,250 sh (New)
John Burbank 1,583,456 sh (+2203.04%)
Joel Greenblatt 242,043 sh (+511.44%)
Jim Simons 2,380,600 sh (+263.28%)
Murray Stahl 30,774 sh (+2.78%)
John Rogers 850,915 sh (+2.31%)
Mario Gabelli 337,588 sh (+1.60%)
Tom Gayner 610,800 sh (+0.93%)
Richard Pzena 1,185,329 sh (+0.92%)
Ken Fisher 10,854,263 sh (+0.35%)
Mairs and Power 2,185,213 sh (+0.04%)
Chuck Royce 9,000 sh (unchged)
Richard Snow 3,260 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Jim Chanos 5,952 sh (unchged)
Richard Perry 292,729 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Ray Dalio Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,327,465 sh (-0.10%)
Jeff Auxier 105,176 sh (-0.24%)
Dodge & Cox 34,808 sh (-1.77%)
Charles Brandes 146,253 sh (-3.20%)
John Buckingham 63,638 sh (-3.21%)
Donald Yacktman 7,080,500 sh (-3.22%)
Pioneer Investments 3,675,335 sh (-3.89%)
John Hussman 25,000 sh (-5.03%)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
Tweedy Browne 3,383,445 sh (-8.39%)
Sarah Ketterer 1,364,323 sh (-8.88%)
Jeremy Grantham 9,036,395 sh (-9.37%)
RS Investment Management 8,397 sh (-12.46%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
Robert Olstein 50,000 sh (-29.58%)
First Eagle Investment 1,142,872 sh (-62.31%)
Paul Tudor Jones 15,876 sh (-65.85%)
PRIMECAP Management 3,023,678 sh (-71.32%)
Ruane Cunniff 13,925 sh (-78.50%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, NYSE:NVS, NYSE:MRK, NYSE:BMY, OTCPK:GLAXF, NYSE:SNY, NYSE:ABBV, NYSE:LLY, OTCPK:BAYRY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:OPHLY, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHY, OTCPK:CHJTF, OTCPK:PTKFF, NAS:ZSPH » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. Baby Care includes the JOHNSON'S line of products. Oral Care includes the LISTERINE product line. Brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON'S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Brands in Women's Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine), and PREZCOBIX/REZOLSTA. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care

Ratios

vs
industry
vs
history
P/E(ttm) 21.02
JNJ's P/E(ttm) is ranked higher than
63% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.68 vs. JNJ: 21.02 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.62 Max: 24
Current: 21.02
10.5
24
Forward P/E 17.64
JNJ's Forward P/E is ranked lower than
62% of the 82 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.75 vs. JNJ: 17.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.02
JNJ's PE(NRI) is ranked higher than
63% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.96 vs. JNJ: 21.02 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.62 Max: 24
Current: 21.02
10.5
24
Price/Owner Earnings (ttm) 19.73
JNJ's Price/Owner Earnings (ttm) is ranked higher than
71% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.84 vs. JNJ: 19.73 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JNJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.19  Med: 17.53 Max: 25.26
Current: 19.73
10.19
25.26
P/B 4.39
JNJ's P/B is ranked lower than
71% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. JNJ: 4.39 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.71 Max: 5.26
Current: 4.39
2.68
5.26
P/S 4.62
JNJ's P/S is ranked lower than
66% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. JNJ: 4.62 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.22 Max: 4.68
Current: 4.62
2.17
4.68
PFCF 22.23
JNJ's PFCF is ranked higher than
53% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.78 vs. JNJ: 22.23 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.28  Med: 16.43 Max: 24.67
Current: 22.23
10.28
24.67
POCF 17.87
JNJ's POCF is ranked lower than
55% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.60 vs. JNJ: 17.87 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 8.98  Med: 13.18 Max: 18.09
Current: 17.87
8.98
18.09
EV-to-EBIT 16.27
JNJ's EV-to-EBIT is ranked higher than
61% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.24 vs. JNJ: 16.27 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.90 Max: 18.2
Current: 16.27
7.8
18.2
EV-to-EBITDA 13.54
JNJ's EV-to-EBITDA is ranked higher than
61% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.55 vs. JNJ: 13.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.90 Max: 14.1
Current: 13.54
6.7
14.1
PEG 3.56
JNJ's PEG is ranked lower than
67% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. JNJ: 3.56 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.19  Med: 1.70 Max: 25.96
Current: 3.56
1.19
25.96
Shiller P/E 24.01
JNJ's Shiller P/E is ranked higher than
76% of the 148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.26 vs. JNJ: 24.01 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.49  Med: 20.94 Max: 29.71
Current: 24.01
15.49
29.71
Current Ratio 2.83
JNJ's Current Ratio is ranked higher than
58% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.42 vs. JNJ: 2.83 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.05 Max: 2.83
Current: 2.83
1.2
2.83
Quick Ratio 2.47
JNJ's Quick Ratio is ranked higher than
62% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. JNJ: 2.47 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.70 Max: 2.47
Current: 2.47
0.94
2.47
Days Inventory 138.04
JNJ's Days Inventory is ranked lower than
63% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. JNJ: 138.04 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 105.89 Max: 137.6
Current: 138.04
100.19
137.6
Days Sales Outstanding 59.32
JNJ's Days Sales Outstanding is ranked higher than
63% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. JNJ: 59.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.4
Current: 59.32
53.94
61.4
Days Payable 100.88
JNJ's Days Payable is ranked higher than
69% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.86 vs. JNJ: 100.88 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 100.88
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.64
JNJ's Dividend Yield is ranked higher than
73% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. JNJ: 2.64 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 1.89  Med: 2.85 Max: 3.84
Current: 2.64
1.89
3.84
Dividend Payout 0.55
JNJ's Dividend Payout is ranked lower than
72% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. JNJ: 0.55 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.41 Max: 6.33
Current: 0.55
0.29
6.33
Dividend Growth (3y) 7.10
JNJ's Dividend Growth (3y) is ranked lower than
51% of the 287 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 7.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13.00 Max: 17.1
Current: 7.1
7
17.1
Forward Dividend Yield 2.77
JNJ's Forward Dividend Yield is ranked higher than
71% of the 564 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. JNJ: 2.77 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.69
JNJ's Yield on cost (5-Year) is ranked higher than
72% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. JNJ: 3.69 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.54  Med: 3.98 Max: 5.39
Current: 3.69
2.54
5.39
3-Year Average Share Buyback Ratio 0.10
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 427 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. JNJ: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -0.10 Max: 2.3
Current: 0.1
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.78
JNJ's Price/Tangible Book is ranked lower than
89% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.41 vs. JNJ: 12.78 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.24  Med: 10.40 Max: 18.92
Current: 12.78
6.24
18.92
Price/Projected FCF 1.69
JNJ's Price/Projected FCF is ranked higher than
65% of the 305 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.43 vs. JNJ: 1.69 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.87  Med: 1.40 Max: 3.6
Current: 1.69
0.87
3.6
Price/DCF (Earnings Based) 1.96
JNJ's Price/DCF (Earnings Based) is ranked lower than
69% of the 72 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. JNJ: 1.96 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.43
JNJ's Price/Median PS Value is ranked lower than
68% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. JNJ: 1.43 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 1.14 Max: 1.88
Current: 1.43
0.74
1.88
Price/Peter Lynch Fair Value 2.55
JNJ's Price/Peter Lynch Fair Value is ranked lower than
75% of the 175 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. JNJ: 2.55 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.23  Med: 1.88 Max: 4.07
Current: 2.55
1.23
4.07
Price/Graham Number 3.45
JNJ's Price/Graham Number is ranked lower than
73% of the 428 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.07 vs. JNJ: 3.45 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 3.15 Max: 5.97
Current: 3.45
1.97
5.97
Earnings Yield (Greenblatt) (%) 6.10
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. JNJ: 6.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.5  Med: 7.80 Max: 12.9
Current: 6.1
5.5
12.9
Forward Rate of Return (Yacktman) (%) 12.26
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. JNJ: 12.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 14.00 Max: 18.4
Current: 12.26
1.8
18.4

More Statistics

Revenue (TTM) (Mil) $70,182
EPS (TTM) $ 5.50
Beta0.80
Short Percentage of Float0.91%
52-Week Range $81.79 - 117.74
Shares Outstanding (Mil)2,750.64

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 71,875 74,772 77,107
EPS ($) 6.60 7.03 7.40
EPS w/o NRI ($) 6.60 7.03 7.40
EPS Growth Rate
(3Y to 5Y Estimate)
2.72%
» More Articles for NYSE:JNJ

Headlines

Articles On GuruFocus.com
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 
Get Higher Returns and More Dividend Income – In Less Time With Less Risk Jun 17 2016 
15 Years With Johnson & Johnson Jun 14 2016 
How to Create Intergenerational Wealth Jun 06 2016 
'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market May 22 2016 
U.S. Stocks Trade Flat at Start of Week May 09 2016 
Johnson & Johnson a Legendary Dividend Stock May 08 2016 
UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
Johnson & Johnson Beats 1st-Quarter Expectations, Improves Guidance Apr 27 2016 
How to Know When You Can Retire With Dividend Investing Apr 13 2016 

More From Other Websites
How Did Roche’s Diagnostics Division Perform? Jun 25 2016
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion Jun 24 2016
Johnson & Johnson :JNJ-US: Earnings Analysis: Q1, 2016 By the Numbers : June 24, 2016 Jun 24 2016
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU Jun 24 2016
There's Value in This High-Dividend ETF Jun 24 2016
Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet... Jun 23 2016
A Secure 4% 'No Withdrawal' Retirement Portfolio Jun 22 2016
Technology Forces Advertisers To Get Creative Jun 22 2016
Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice... Jun 22 2016
Johnson & Johnson Names Joseph Wolk As VP Of Investor Relations In Place Of Louise Mehrotra Jun 22 2016
Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice... Jun 22 2016
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results Jun 21 2016
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results Jun 21 2016
Countdown to Brexit Jun 21 2016
Commercial Vehicle Group, Houlihan Lokey, Johnson & Johnson and Canadian Imperial Bank of Commerce... Jun 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)